15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract

          Baculoviruses are insect pathogens widely used as biotechnological tools in different fields of life sciences and technologies. The particular biology of these entities (biosafety viruses 1; large circular double-stranded DNA genomes, infective per se; generally of narrow host range on insect larvae; many of the latter being pests in agriculture) and the availability of molecular-biology procedures ( e.g., genetic engineering to edit their genomes) and cellular resources (availability of cell lines that grow under in vitro culture conditions) have enabled the application of baculoviruses as active ingredients in pest control, as systems for the expression of recombinant proteins (Baculovirus Expression Vector Systems—BEVS) and as viral vectors for gene delivery in mammals or to display antigenic proteins (Baculoviruses applied on mammals—BacMam). Accordingly, BEVS and BacMam technologies have been introduced in academia because of their availability as commercial systems and ease of use and have also reached the human pharmaceutical industry, as incomparable tools in the development of biological products such as diagnostic kits, vaccines, protein therapies, and—though still in the conceptual stage involving animal models—gene therapies. Among all the baculovirus species, the Autographa californica multiple nucleopolyhedrovirus has been the most highly exploited in the above utilities for the human-biotechnology field. This review highlights the main achievements (in their different stages of development) of the use of BEVS and BacMam technologies for the generation of products for infectious and noninfectious human diseases.

          Key points

          Baculoviruses can assist as biotechnological tools in human health problems.

          Vaccines and diagnosis reagents produced in the baculovirus platform are described.

          The use of recombinant baculovirus for gene therapy–based treatment is reviewed.

          Related collections

          Most cited references254

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A serological assay to detect SARS-CoV-2 seroconversion in humans

            Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              From SARS to MERS, Thrusting Coronaviruses into the Spotlight

              Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused high pathogenicity and mortality rates in human populations. This brought CoVs global attention and highlighted the importance of controlling infectious pathogens at international borders. In this review, we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable animal models, we compare the current animal models recapitulating pathogenesis and summarize the potential role of host receptors contributing to diverse host affinity in various species. We outline the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV and MERS-CoV, but also these emerging coronaviral diseases.
                Bookmark

                Author and article information

                Contributors
                atargovnik@yahoo.com
                Journal
                Appl Microbiol Biotechnol
                Appl Microbiol Biotechnol
                Applied Microbiology and Biotechnology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0175-7598
                1432-0614
                7 October 2021
                : 1-32
                Affiliations
                [1 ]GRID grid.7345.5, ISNI 0000 0001 0056 1981, Cátedra de Biotecnología, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, , Universidad de Buenos Aires, ; Junín 956, Buenos Aires, 1113 Argentina
                [2 ]GRID grid.7345.5, ISNI 0000 0001 0056 1981, Instituto de Nanobiotecnología (NANOBIOTEC), Facultad de Farmacia y Bioquímica, , CONICET -Universidad de Buenos Aires, ; Junín 956, Sexto Piso, C1113AAD, 1113 Buenos Aires, Argentina
                [3 ]GRID grid.11560.33, ISNI 0000 0001 1087 5626, Laboratorio de Ingeniería Genética y Biología Celular y Molecular, Área Virosis de Insectos, Instituto de Microbiología Básica y Aplicada, Departamento de Ciencia y Tecnología, , Universidad Nacional de Quilmes, ; Buenos Aires, Argentina
                Author information
                http://orcid.org/0000-0003-4480-031X
                Article
                11615
                10.1007/s00253-021-11615-1
                8495437
                34618205
                3174566a-9879-41c5-935d-3e61c45c0567
                © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 4 August 2021
                : 20 September 2021
                : 21 September 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100002923, consejo nacional de investigaciones científicas y técnicas;
                Award ID: PIP 00224/15
                Award ID: PUE 0045
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100007351, secretaria de ciencia y tecnica, universidad de buenos aires;
                Award ID: UBACyT 2016-20020150100145BA
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100009559, universidad nacional de quilmes;
                Award ID: PPROF-2020
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100006668, fondo para la investigación científica y tecnológica;
                Award ID: PICT 2015-1992
                Award ID: 2015-1992
                Award ID: PICT 2018-4321
                Award Recipient :
                Categories
                Mini-Review

                Biotechnology
                baculovirus,acmnpv,bevs,bacmam,human diseases
                Biotechnology
                baculovirus, acmnpv, bevs, bacmam, human diseases

                Comments

                Comment on this article